Tectonic Therapeutic (TECX)

Overall impact
C (58)

Commentary

Avrobio is an average overall performer. With a 'C' rating of 57.6 for overall impact (58th percentile compared to all companies), Avrobio ranks 442nd out of 585 industry peers, behind Biogen, Ionis Pharmaceuticals, Gilead Sciences and 438 others, and ahead of Grifols, Jazz Pharmaceuticals, Gb Sciences and 140 others. On top material causes for Avrobio's industry (Pharmaceuticals & Biotech), Avrobio performs well in Child and Maternal Health (85.3 score), Child and Maternal Health (92.8) and Disease Eradication (96.4) and performs poorly in Sustainable Use of Water (32.8 score), Decent, Safe Work Opportunities (29.6) and Disaster Readiness and Effective Aid (28.7).
Impact
Cause TECX
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
2015
Employees
60
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Ma, United States
Share classes
TECX
Description
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
Material causes
Ethos considers the following causes material for Tectonic Therapeutic, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.